Stocks and Investing Stocks and Investing
Fri, June 30, 2023

Graig Suvannavejh Reiterated (BTAI) at Strong Buy and Held Target at $40 on, Jun 30th, 2023


Published on 2024-10-28 04:35:58 - WOPRAI, Graig Suvannavejh
  Print publication without navigation


Graig Suvannavejh of Mizuho, Reiterated "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy and Held Target at $40 on, Jun 30th, 2023.

Graig has made no other calls on BTAI in the last 4 months.



There are 4 other peers that have a rating on BTAI. Out of the 4 peers that are also analyzing BTAI, 2 agree with Graig's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Corinne Jenkins of "Goldman Sachs" Maintained at Hold with Decreased Target to $25 on, Friday, May 26th, 2023
  • Chris Howerton of "Jefferies" Downgraded from Strong Buy to Hold and Increased Target to $22 on, Friday, March 10th, 2023


These are the ratings of the 2 analyists that currently disagree with Graig


  • Raghuram Selvaraju of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $66 on, Tuesday, May 30th, 2023
  • Yatin Suneja of "Guggenheim" Maintained at Strong Buy with Decreased Target to $46 on, Tuesday, May 9th, 2023
Contributing Sources